Ascendis Pharma is a global biopharmaceutical company that uses its proprietary TransCon platform to develop long-acting therapies for endocrinology rare diseases and oncology. The company has marketed two FDA-approved products for hypoparathyroidism and growth hormone deficiency, and maintains a clinical pipeline including candidates for achondroplasia and solid tumors. Ascendis generates revenue through direct product sales, milestone and royalty payments from strategic partners such as Novo Nordisk and Teijin, and equity stakes in joint ventures, while leveraging its core technology to build a portfolio of therapies addressing significant unmet medical needs.